Across TCGA pan-cancer cohorts, RNF138 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RNF138 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RNF138 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNF138 expression acts as an unfavorable survival marker.
CESC, THYM, and COAD are the cancer types where RNF138 Mutation most reproducibly stratifies survival.